Terms: = Breast cancer AND TOP2A, TOP2, TP2A AND Diagnosis
15 results:
1. Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis.
Ma J; Chen C; Liu S; Ji J; Wu D; Huang P; Wei D; Fan Z; Ren L
Cancer Gene Ther; 2022 Nov; 29(11):1578-1589. PubMed ID: 35474355
[TBL] [Abstract] [Full Text] [Related]
2. [Screening of differentially expressed genes for colorectal cancer and prediction of potential traditional Chinese medicine: based on bioinformatics].
Yun ZJ; Wang HJ; Yu YX; Sun ZY; Yao SK
Zhongguo Zhong Yao Za Zhi; 2022 Mar; 47(6):1666-1676. PubMed ID: 35347966
[TBL] [Abstract] [Full Text] [Related]
3. Hsa-mir-3163 and CCNB1 may be potential biomarkers and therapeutic targets for androgen receptor positive triple-negative breast cancer.
Qiu P; Guo Q; Yao Q; Chen J; Lin J
PLoS One; 2021; 16(11):e0254283. PubMed ID: 34797837
[TBL] [Abstract] [Full Text] [Related]
4. Identification of candidate biomarkers correlated with the pathogenesis and prognosis of breast cancer via integrated bioinformatics analysis.
Liu S; Liu X; Wu J; Zhou W; Ni M; Meng Z; Jia S; Zhang J; Guo S; Lu S; Li Y
Medicine (Baltimore); 2020 Dec; 99(49):e23153. PubMed ID: 33285689
[TBL] [Abstract] [Full Text] [Related]
5. Identification of core genes and potential molecular mechanisms in breast cancer using bioinformatics analysis.
Liu F; Wu Y; Mi Y; Gu L; Sang M; Geng C
Pathol Res Pract; 2019 Jul; 215(7):152436. PubMed ID: 31076281
[TBL] [Abstract] [Full Text] [Related]
6. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
An X; Xu F; Luo R; Zheng Q; Lu J; Yang Y; Qin T; Yuan Z; Shi Y; Jiang W; Wang S
BMC Cancer; 2018 Mar; 18(1):331. PubMed ID: 29587760
[TBL] [Abstract] [Full Text] [Related]
7. ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A Review.
Botti G; Malzone MG; La Mantia E; Montanari M; Vanacore D; Rossetti S; Quagliariello V; Cavaliere C; Di Franco R; Castaldo L; Ametrano G; Cappuccio F; Romano FJ; Piscitelli R; Pepe MF; D'Aniello C; Facchini G
Int J Med Sci; 2017; 14(6):554-559. PubMed ID: 28638271
[TBL] [Abstract] [Full Text] [Related]
8. Amplification of HER2 and top2a and deletion of top2a genes in a series of Taiwanese breast cancer.
Chen JR; Chien HP; Chen KS; Hwang CC; Chen HY; Yeh KY; Hsieh TY; Chang LC; Hsu YC; Lu RJ; Hua CC
Medicine (Baltimore); 2017 Jan; 96(2):e5582. PubMed ID: 28079792
[TBL] [Abstract] [Full Text] [Related]
9. Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.
Bai Y; Li LD; Li J; Lu X
J Ovarian Res; 2016 Jun; 9(1):35. PubMed ID: 27315793
[TBL] [Abstract] [Full Text] [Related]
10. RRM1, TUBB3, top2a, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
Xu YC; Zhang FC; Li JJ; Dai JQ; Liu Q; Tang L; Ma Y; Xu Q; Lin XL; Fan HB; Wang HX
Oncol Rep; 2015 Oct; 34(4):1883-94. PubMed ID: 26252353
[TBL] [Abstract] [Full Text] [Related]
11. Tissue-specific selection of optimal reference genes for expression analysis of anti-cancer drug-related genes in tumor samples using quantitative real-time RT-PCR.
Wang H; Yang B; Geng T; Li B; Dai P; Chen C
Exp Mol Pathol; 2015 Jun; 98(3):375-81. PubMed ID: 25445497
[TBL] [Abstract] [Full Text] [Related]
12. top2a gene copy number change in breast cancer.
Engstrøm MJ; Ytterhus B; Vatten LJ; Opdahl S; Bofin AM
J Clin Pathol; 2014 May; 67(5):420-5. PubMed ID: 24403186
[TBL] [Abstract] [Full Text] [Related]
13. top2a overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.
Lan J; Huang HY; Lee SW; Chen TJ; Tai HC; Hsu HP; Chang KY; Li CF
Tumour Biol; 2014 Jan; 35(1):179-87. PubMed ID: 23897556
[TBL] [Abstract] [Full Text] [Related]
14. Hypermethylation of TUSC5 genes in breast cancer tissue.
Bubnov V; Moskalev E; Petrovskiy Y; Bauer A; Hoheisel J; Zaporozhan V
Exp Oncol; 2012 Dec; 34(4):370-2. PubMed ID: 23302999
[TBL] [Abstract] [Full Text] [Related]
15. Among triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results.
Nakagawa M; Bando Y; Nagao T; Takai C; Ohnishi T; Honda J; Moriya T; Izumi K; Takahashi M; Tangoku A; Sasa M
Breast Cancer; 2012 Jan; 19(1):54-9. PubMed ID: 21465226
[TBL] [Abstract] [Full Text] [Related]
